Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD117 expression in diffuse large B-cell lymphomas: fact or fiction?

Efsevia Vakiani1, Giorgio Cattoretti, Adriana I Colovai

  • 1Department of Pathology, Columbia University, New York, NY, USA.

Pathology International
|November 8, 2005
PubMed
Summary

CD117 (KIT) is sporadically detected in diffuse large B-cell lymphomas (DLBCL) and plasmablastic lymphomas. Careful antibody validation is crucial to avoid false positives in DLBCL diagnostics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism.

Gut·2026
Same author

Challenges of chimerism analysis using Next-Generation sequencing in a patient with complex chromosomal alterations.

Human immunology·2026
Same author

Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.

Leukemia & lymphoma·2026
Same author

Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism.

bioRxiv : the preprint server for biology·2026
Same author

Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma.

JCO precision oncology·2026
Same author

The normal human lymph node cell classification and landscape defined by high-dimensional spatial proteomics.

PloS one·2026

Area of Science:

  • Hematology
  • Oncology
  • Immunohistochemistry

Background:

  • CD117 (KIT) expression is documented in various hematopoietic neoplasms.
  • Data on CD117 expression in diffuse large B-cell lymphomas (DLBCL) is limited.
  • This study investigates CD117 expression in DLBCL and plasmablastic lymphomas.

Observation:

  • Two CD117+ DLBCL cases were identified: one of follicle center-cell origin and one EBV-associated plasmablastic lymphoma with bone lesions.
  • Tissue microarrays and seven additional plasmablastic lymphomas were analyzed using two anti-CD117 antibodies (Ab-1 and A4502).
  • Ab-1 showed staining in 37% of DLBCL cases, while A4502 showed staining only in specific cases.

Findings:

  • CD117 expression is sporadically present in DLBCL of follicle center-cell origin and a subset of plasmablastic lymphomas.

Related Experiment Videos

  • CD117 staining may aid in identifying EBV-plasmablastic lymphomas with bone marrow involvement.
  • Non-specific staining with certain antibodies (e.g., Ab-1) can lead to false-positive results, highlighting the need for antibody validation.

    • Implications:

    • CD117 expression is a potential, albeit infrequent, marker in specific DLBCL subtypes.
    • Accurate CD117 detection is vital for correct diagnosis and subtyping of lymphomas.
    • Standardization and validation of CD117 antibodies are essential for reliable diagnostic applications in hematopathology.